The reSept ASD Occluder has been implanted in the first patient in Nantes, as part of the ASCENT ASD trial. Nantes University Hospital CHU is one of the few centers in France currently taking part in the ASCENT ASD trial in Europe.
The intervention was conducted by the team led by Professor Alban Baruteau, Head of the Pediatric and Congenital Cardiology Medical-Surgical Department at CHU Nantes.
“Assessing a novel technology that may improve current and future treatment for patients with congenital heart conditions, like atrial septal defects, is important for the progression of clinical research and healthcare,” said Professor Baruteau. “We are pleased to be able to offer this option to patients in the Nantes area, as part of this clinical study.”
The ASCENT ASD trial is a French ANSM and US FDA-approved clinical study to assess the safety and efficacy of the reSept ASD occluder, the first transcatheter septal occluder with a metal-free frame. The trial is currently enrolling patients in four centers in France, including Bordeaux, Nantes, Paris and Toulouse and in several study centers in the United States.
“The ongoing enrollment of patients in France and in the USA is very promising in the journey to bring a solution for atrial septal defects that may leave less metal behind,” said Laurent Grandidier, atHeart Medical CEO. “We are delighted to add CHU Nantes to the list of prestigious hospitals participating in the ASCENT trial”.